Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

The limited clinical trial represents the first human implantation of a cardiac auscultation sensor device

News | Heart Failure

Canary Completes First-in-Human Trial of Cardiac Auscultation Monitoring Sensor

February 15, 2024 — Canary Medical, a medical data company focused on the development and commercialization of its ...

February 15, 2024

Panel of independent experts reviewed data from the TRILUMINATE pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system

News | Structural Heart

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee ...

February 15, 2024

The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or high blood pressure, in older adults without increasing their risk of low blood pressure episodes, according to a study published in the Feb. 2024 issue of the Journal of the American College of Cardiology (JACC).

News | Hypertension

DECIDE-Salt Study Finds Salt Substitutes Help to Maintain Healthy Blood Pressure in Older Adults

February 14, 2024 — The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or ...

February 14, 2024

Cleerly has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging

News | Artificial Intelligence

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

February 13, 2024 — Cleerly, a digital healthcare company focused on artificial intelligence (AI)-driven heart disease ...

February 13, 2024

A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health.

News | Heart Failure

Allina Health Minneapolis Heart Institute is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure

February 12, 2023 — A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully ...

February 12, 2024

On the final day of the American Stroke Association’s International Stroke Conference 2024, ISC 2024, findings from the EMBOLISE clinical trial were presented by Jason Davies, M.D., Ph.D., an associate professor in the departments of neurosurgery and biomedical informatics at the State University of New York, Buffalo.

News | AHA

ISC 2024 News: Late-Breaking Science Findings from EMBOLISE Clinical Trial Reveals Blocking Artery Supplying the Brain Covering After Subdural Hematoma Reduced Repeat Surgery

February 9, 2024 — Injection of a substance to block an artery feeding the dura (protective sack around the brain) — ...

February 09, 2024

Physicians in the Smidt Heart Institute at Cedars-Sinai have pioneered using a catheter-based approach to treat patients with tricuspid valve disease. Image by Getty.

News | Structural Heart

Smidt Heart Institute Physicians Advance Transcatheter Tricuspid Valve Replacement

February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts ...

February 09, 2024

ResearcherLate-breaking science from the American Stroke Association’s International Stroke Conference, ISC 2024, reports researchers found an artificial intelligence (AI) system to help guide treatment decisions for stroke patients led to improved stroke care quality and fewer recurrent strokes, heart attacks and vascular death among stroke survivors three months after a stroke.

News | AHA

International Stroke Conference Researcher Finds AI-based System Helped Guide Treatment, Lowered Stroke Recurrence

February 8, 2024 — The latest late-breaking science from the second day of the American Stroke Association’s Internation ...

February 08, 2024

This new document builds off of the previously published Best Practices for Consumer Cardiovascular Technology Solutions in January 2022.

News | ACC

CTA and ACC Collaborate to Tackle Cardiovascular Disease with Technology

February 7, 2024 — The Consumer Technology Association (CTA) and the American College of Cardiology (ACC) are announcing ...

February 07, 2024

New phenomapping tool and clinical score could lead to personalized strategies for patients hospitalized with ADHF

News | Artificial Intelligence

Machine Learning Informs a New Tool to Guide Treatment for Acute Decompensated Heart Failure

February 6, 2024 — A recent study co-authored by Dr. Matthew Segar, a third-year cardiovascular disease fellow at The ...

February 06, 2024

ATTRibute-CM results also demonstrated rapid clinical benefit on the composite endpoint of all-cause mortality (ACM) and CVH in patients treated with acoramidis, with time-to-first event Kaplan-Meier curves separating at month 3 and continuing to diverge steadily through Month 30

News | FDA

BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

February 6, 2024 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

February 06, 2024

The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.

News | FDA

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy Earns FDA Approval for Tricuspid Valve

February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is ...

February 02, 2024

In addressing efficacy, harm, and logistics, the study passes all three of the criteria suggested by the American Heart Association guiding the implementation of polygenic risk scores (PRSs) in cardiovascular care

News | Cardiovascular Clinical Studies

Genomics plc Publishes Clinical Trial Results Demonstrating Successful Integration and Clinical Utility of Integrated Risk Scores Combining Polygenic and Clinical Risk of Cardiovascular Disease in NHS Primary Care

February 1, 2024 — Genomics plc (Genomics), a healthcare company aiming to transform health through the power of ...

February 01, 2024

As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, ITN has compiled a snapshot of significant cardiovascular disease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market.

Feature | Cardiovascular Education | Christine Book

American Heart Month Puts Spotlight on Cardiovascular Disease and Stroke Statistics

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country ...

February 01, 2024

Here is a look at the most-read content during the month of January on dicardiology.com

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Top 10: What Viewers Were Reading in January

It is a new year with lots of new content! Here is a look at the most-read content during the month of January on dicard ...

February 01, 2024